Measuring HIV-1-specific T cell immunity: How valid are current assays?

Journal of Infectious Diseases

Volumn 197, Issue 3, 2008, Pages 337-339

  D'Souza, M Patricia ^a   Altfeld, Marcus ^b,c,d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Partners AIDS Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CELLULAR IMMUNITY; CLINICAL TRIAL; EDITORIAL; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS TRANSMISSION;

AIDS VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CROSS REACTIONS; HIV INFECTIONS; HIV-1; HUMANS; MUTAGENESIS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 39349090265     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/525288     Document Type: Editorial

References (22)

1. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004; 10:806-10.
2. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-10.
3. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-5.
4. + lymphocytes. Science 1999; 283:857-60.
5. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405-11.
6. Gao X, Bashirova A, Iversen AK, et al. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med 2005; 11:1290-2.
7. Phillips RE, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991; 354:453-9.
8. Goulder PJ, Watkins DI. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 2004; 4:630-40.
9. Addo MM, Yu XG, Rathod A, et al. comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003; 77:2081-92.
10. Frahm N, Korber BT, Adams CM, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004; 78:2187-200.
11. Yang OO, Kalams SA, Rosenzweig M, et al. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J Virol 1996; 70:5799-806.
12. Yang OO, Nguyen PT, Kalams SA, et al. Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J Virol 2002; 76:1626-31.
13. + cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 1997; 71:3120-8.
14. Yang OO, Sarkis PT, Ali A, et al. Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J Exp Med 2003; 197:1365-75.
15. + T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 2007; 178:2746-54.
16. + T cells recognize SIV-infected cells before Nef-mediated major histocompatibility complex class I downregulation. J Virol 2007; 81:11703-12.
17. Bennett MS, Ng HL, Ali A, Yang OO. Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity. J Infect Dis 2008: 197;390-7 (in this issue).
18. McDermott AB, Mitchen J, Piaskowski S, et al. Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J Virol 2004; 78:3140-4.
19. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McElrath MJ. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis 2003; 187:226-42.
20. Horton H, Thomas EP, Stucky JA, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 2007; 323: 39-54.
21. National Institute of Allergy and Infectious Diseases. Immunizations are discontinued in two HIV vaccine trials. Press release, 21 September 2007. Available at: http://www3.niaid.nih.gov/news/newsreleases/2007/step_statement. htm. Accessed 20 December 2007.
22. Saez-Cirion A, Lacabaratz C, Lambotte O, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007; 104:6776-81.